脐血干细胞联合人参促分化合剂治疗失代偿期肝硬化疗效研究

发布时间：2018-06-28 00:38

  本文选题：胎血 + 脐血干细胞移植　； 参考：《中国全科医学》2015年02期

【摘要】：目的探讨脐血干细胞联合人参促分化合剂治疗失代偿期肝硬化的疗效。方法选择2012年2月—2013年4月衡水市哈励逊国际和平医院消化内科确诊的失代偿期肝硬化患者30例,术前行常规保肝治疗,采用细胞分离技术从脐带血中提取干细胞,经肝固有动脉将干细胞悬液移植入肝脏。移植成功后给予人参促分化合剂辅助治疗,治疗14 d。治疗后第16周观察患者肝功能指标,包括ALT、AST、清蛋白(Alb)、总胆红素(TBi L)、凝血酶原活动度(PTA);治疗后第24周观察血清学纤维化指标,包括透明质酸(HA)、层粘连蛋白(LN)、Ⅲ型前胶原(PC-Ⅲ)、Ⅳ型胶原(Ⅳ-C);治疗后第24周行CT检查,观察肝脏影像学变化,包括肝脏最大截面积和肝脏平扫CT值。结果治疗后第16周,患者血浆ALT、AST、TBi L低于治疗前,Alb、PTA高于治疗前(P0.05)。治疗后第24周,患者HA、PC-Ⅲ、Ⅳ-C、LN均低于治疗前(P0.05)。治疗后第24周,患者肝脏最大截面积多于治疗前(P0.05);治疗前后,肝脏平扫CT值比较,差异无统计学意义(P0.05)。结论脐血干细胞联合人参促分化合剂可以改善失代偿期肝硬化患者肝功能,修复肝脏损伤,是临床治疗失代偿期肝硬化的一种有效措施。
[Abstract]:Objective to investigate the therapeutic effect of cord blood stem cells combined with ginseng promoting differentiation mixture in the treatment of decompensated cirrhosis. Methods from February 2012 to April 2013, 30 patients with decompensated cirrhosis diagnosed by Department of Digestive Medicine, Hallieson International Peace Hospital, Hengshui City, were treated with routine hepatoprotective therapy. Stem cells were extracted from umbilical cord blood by cell separation technique. Stem cell suspension was transplanted into the liver via the proper hepatic artery. After successful transplantation, ginseng promoting differentiation mixture was given adjuvant treatment for 14 days. The indexes of liver function including alt AST, total bilirubin (TBiL) and prothrombin activity (PTA) of serum albumin (Alb), were observed at the 16th week after treatment, and the serum fibrosis indexes were observed at the 24th week after treatment. Hyaluronic acid (HA), laminin (LN), procollagen 鈪，

本文编号：2075927